Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.50 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.50 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.50 |
| ▸ | GJB2 | P29033 | 5/20 | 0.49 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.45 |
| ▸ | AMY2A | P04746 | 4/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8439367 | 1.00 | LGALS8 (0.50) | LGALS8LGALS3LGALS4GJB2ENGASE | |
| SCHEMBL9804026 | 0.95 | LGALS8 (0.54) | LGALS8LGALS3LGALS4GJB2ENGASE | |
| SCHEMBL412539 | 0.95 | LGALS8 (0.54) | LGALS8LGALS3LGALS4GJB2ENGASE | |
| SCHEMBL8491597 | 0.90 | LGALS3 (0.52) | LGALS8LGALS3LGALS4ENGASEAMY2A | |
| SCHEMBL17688998 | 0.88 | LGALS8 (0.52) | LGALS8LGALS3LGALS4GJB2AMY2A | |
| SCHEMBL18160495 | 0.87 | LGALS8 (0.49) | LGALS8LGALS3LGALS4GJB2ENGASE | |
| SCHEMBL8970600 | 0.87 | LGALS8 (0.48) | LGALS8LGALS3LGALS4ENGASEAMY2A | |
| SCHEMBL17688995 | 0.87 | LGALS3 (0.51) | LGALS8LGALS3LGALS4ENGASEAMY2A | |
| SCHEMBL8435122 | 0.87 | LGALS8 (0.48) | LGALS8LGALS3LGALS4ENGASEAMY2A | |
| SCHEMBL2329201 | 0.87 | LGALS3 (0.51) | LGALS8LGALS3LGALS4ENGASEAMY2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179493-B2 | Methods and compositions for inducing multi-targeted healing of intervertebral disc defects | ROWAN UNIVERSITY (US) | 2021-11-23 | — | — | US | claimed |
| US-20190117831-A1 | METHODS AND COMPOSITIONS FOR INDUCING MULTI-TARGETED HEALING OF INTERVERTEBRAL DISC DEFECTS | ROWAN UNIVERSITY | 2019-04-25 | — | — | US | claimed |
| WO-2017176973-A1 | METHODS AND COMPOSITIONS FOR INDUCING MULTI-TARGETED HEALING OF INTERVERTEBRAL DISC DEFECTS | ROWAN UNIVERSITY (US) | 2017-10-12 | — | — | WO | claimed |
| US-11179493-B2 | Methods and compositions for inducing multi-targeted healing of intervertebral disc defects | ROWAN UNIVERSITY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20190117831-A1 | METHODS AND COMPOSITIONS FOR INDUCING MULTI-TARGETED HEALING OF INTERVERTEBRAL DISC DEFECTS | ROWAN UNIVERSITY | 2019-04-25 | — | — | US | disclosed |
| WO-2017176973-A1 | METHODS AND COMPOSITIONS FOR INDUCING MULTI-TARGETED HEALING OF INTERVERTEBRAL DISC DEFECTS | ROWAN UNIVERSITY (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20080076736-A1 | COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | SKY HIGH, LLC (US) | 2008-03-27 | — | — | US | disclosed |
| US-7259273-B1 | Compositions containing lysophosphotidic acids which inhabit apoptosis and uses thereof | GODDARD JOHN G | 2007-08-21 | — | — | US | disclosed |
| EP-1024812-B1 | COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | SKY HIGH LLC (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060063738-A1 | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof | SKY HIGH, LLC (US) | 2006-03-23 | — | — | US | disclosed |
| US-6949529-B2 | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof | SKY HIGH, LLC (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1069895-A4 | COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | LXR BIOTECHNOLOGY INC (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-1069895-A2 | COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | LXR BIOTECHNOLOGY INC. (US) | 2001-01-24 | — | — | EP | disclosed |
| EP-1024812-A1 | COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | LXR BIOTECHNOLOGY INC. (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999047101-A2 | COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | LXR BIOTECHNOLOGY, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999008514-A1 | COMPOSITIONS CONTAINING POLYETHYLENE GLYCOL AND USES THEREOF | LXR BIOTECHNOLOGY, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1998041213-A1 | COMPOSITIONS CONTAINING LYSOPHOSPHOTIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | LXR BIOTECHNOLOGY INC. (US) | 1998-09-24 | — | — | WO | disclosed |
| WO-1998029579-A1 | METHOD OF DEPOSITING A METALLIC FILM | COATES BROTHERS PLC (GB) | 1998-07-09 | — | — | WO | disclosed |
| EP-0717999-A1 | Drug delivery composition | THE UNIVERSITY OF MIAMI (US) | 1996-06-26 | — | — | EP | disclosed |
| US-5384333-A | Time release agents | UNIVERSITY OF MIAMI (US) | 1995-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076736-A1 | COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | LPAR6, LPAR1, LPAR3 | LGALS8 679/4885LGALS3 312/4885LGALS4 537/4885 |
| US-20060063738-A1 | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof | LPAR5, LPAR2, LPAR6 | LGALS8 703/4885LGALS3 600/4885LGALS4 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.